Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Summary

Glenmark Pharmaceuticals Inc., USA announced the launch of Sugammadex Injection in two formulations (200 mg/2 mL and 500 mg/5 mL single-dose vials). The product is a generic/bioequivalent formulation of the neuromuscular blocking agent reversal agent.